CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-11-14 | ASELAGE STEVE Chief Executive Officer | Sale | −4,950 | $23.63 | $117K | 259,433 |
| 2018-11-14 | ASELAGE STEVE Chief Executive Officer | Sale | −600 | $24.58 | $15K | 258,833 |
| 2018-11-09 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award | +5,000 | 22,992 | ||
| 2018-11-09 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +5,000 | 22,827 | ||
| 2018-11-09 | McFarlane Neil F. Chief Operating Officer | Grant or award | +10,000 | 38,476 | ||
| 2018-11-09 | Clague Laura Chief Financial Officer | Grant or award | +7,500 | 19,533 | ||
| 2018-11-09 | ASELAGE STEVE Chief Executive Officer | Grant or award | +18,500 | 264,383 | ||
| 2018-08-31 | ASELAGE STEVE Chief Executive Officer | Option exercise | +12,000 | $8.70 | $104K | 257,883 |
| 2018-08-31 | ASELAGE STEVE Chief Executive Officer | Sale | −12,000 | $32.00 | $384K | 245,883 |
| 2018-08-31 | ASELAGE STEVE Chief Executive Officer | Option exercise · Employee stock option (right to buy) | −12,000 | 0 | ||
| 2018-07-26 | Rosenberg Noah L. Chief Medical Officer | Grant or award | +10,000 | 10,000 | ||
| 2018-07-26 | Rosenberg Noah L. Chief Medical Officer | Grant or award · Employee stock option (right to buy) | +65,000 | 65,000 | ||
| 2018-07-26 | Rosenberg Noah L. Chief Medical Officer | Grant or award · Performance-based restricted stock units | +10,000 | 10,000 | ||
| 2018-05-10 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award | +6,500 | 17,656 | ||
| 2018-05-10 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award · Employee stock option (right to buy) | +39,000 | 39,000 | ||
| 2018-05-10 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award · Performance-based restricted stock units | +6,500 | 6,500 | ||
| 2018-05-10 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +7,000 | 17,827 | ||
| 2018-05-10 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award · Employee stock option (right to buy) | +42,000 | 42,000 | ||
| 2018-05-10 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award · Performance-based restricted stock units | +7,000 | 7,000 | ||
| 2018-05-10 | McFarlane Neil F. Chief Operating Officer | Grant or award | +10,500 | 27,948 |
Page 50 of 51 · 1,020 trades